인간의 혈액 - 뇌척수액 장벽의 맥락총 상피 세포 기반 모델은 기저 측면에서 세균 감염을 연구하는

Executive Industry Relevance

This model enables mechanistic de-risking of CNS-targeted therapeutics by simulating pathogen interactions at the blood-cerebrospinal fluid barrier from the physiologically relevant basolateral side. It supports target validation and assay development for anti-infective strategies against meningitis-causing bacteria like N. meningitidis. The system provides predictive confidence in early discovery by quantifying bacterial invasion and adhesion through standardized TEER and permeability readouts.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses regarding bacterial virulence factors and host-pathogen interactions at the BCSFB.
• Operational Value: Enables functional target validation via quantitative measurement of pathogen invasion and adhesion using double immunofluorescence.
• Predictive Value: Supports portfolio triage by identifying compounds that reduce bacterial translocation across epithelial barriers.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for high-throughput screening of antimicrobial compounds.
• Operational Value: Delivers standardized, reproducible TEER and FITC-inulin permeability assays for barrier integrity assessment.
• Scalability: Enables platform reuse across pathogen strains and compound libraries with defined multiplicity of infection (MOI=10) protocols.

Translational & Preclinical Research

• Translational Continuity: Models disease-relevant CNS infection pathways applicable to neurodegenerative and neuroinflammatory conditions.
• Preclinical Alignment: Connects early discovery to mechanistic de-risking of CNS-penetrant therapeutics.
• Risk-Adjusted Decisions: Informs go/no-go criteria based on pathogen-induced barrier disruption thresholds.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, specifically for CNS infectious disease programs.

• Discovery Biology: Supports hypothesis testing of bacterial transmigration mechanisms and pathway clarification of virulence factor engagement.
• Screening: Delivers assay readiness through TEER stabilization (>500 Ω·cm²) and low macromolecular permeability baselines.
• Analytics: Provides quantitative readouts of invaded and adhered bacteria via fluorescence intensity, enabling dose-response and inhibition profiling.
• Translational Research: Connects to preclinical continuity by modeling human-relevant BCSFB pathophysiology in infection and metastasis contexts.
• Enterprise Reuse: Establishes a reusable platform for studying immune, tumor, and pathogen cell migration across choroid plexus epithelium.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity in CNS infection models.
• Operational Value: Standardization of barrier assays, reproducibility across inserts, scalability to 24-well formats.
• Strategic Value: Better go/no-go decisions on CNS-active compounds, capital efficiency via early de-risking, reduced late-stage biological failure risk.
• Portfolio Impact: Risk-adjusted prioritization of antimicrobial leads based on barrier penetration efficacy.

Implementation Considerations

• Requires expertise in primary cell culture, tight junction biology, and pathogen handling under BSL-2 conditions.
• Dependent on epithelial tissue volt-ohm meters for TEER, fluorescence microscopes for immunofluorescence, and plate readers for permeability assays.
• Necessitates cross-team standardization of infection timing, MOI, and wash protocols between virology, microbiology, and assay development groups.
• Adaptation considerations include varying pore sizes, coating matrices, and infection durations for different pathogen models.
• Practical limitations include susceptibility to mechanical disruption of the epithelial layer during insert handling and variability in TEER maturation timelines.

Biopharma FAQs